Real-World Safety Profile of Esaxerenone: Focus on Hyperkalemia

Abstract

Esaxerenone, a novel non-steroidal mineralocorticoid receptor antagonist (MRA), has emerged as a significant therapeutic option for hypertension and chronic kidney disease (CKD) with proteinuria. While esaxerenone offers clinical benefits, the risk of hyperkalemia remains a critical safety concern, especially in real-world settings. This review synthesizes recent evidence on the safety profile of esaxerenone, focusing on the incidence, risk factors, pathophysiology, and management of hyperkalemia. Emphasis is placed on practical considerations for healthcare providers, integrating clinical trial data, post-marketing surveillance, and guideline recommendations to optimize patient outcomes while mitigating adverse events.

Introduction

Mineralocorticoid receptor antagonists have long been integral in managing hypertension and cardiorenal disorders. Esaxerenone distinguishes itself from traditional agents with improved receptor selectivity and a favorable pharmacokinetic profile. Despite these advantages, the propensity for inducing hyperkalemia—potentially life-threatening if unrecognized—requires vigilant monitoring and evidence-based management. Understanding how esaxerenone's safety profile translates from clinical trials to heterogeneous real-world populations is paramount for safe prescribing, especially among patients with comorbidities or polypharmacy.

Epidemiology / Disease Burden

Hypertension and CKD are prevalent global health burdens, with millions at risk for cardiovascular and renal complications. MRAs, including esaxerenone, have demonstrated efficacy in reducing morbidity and mortality, particularly in proteinuric CKD and resistant hypertension. However, the risk of hyperkalemia can limit their use, especially in populations with declining renal function or concomitant use of other renin-angiotensin-aldosterone system (RAAS) inhibitors. Real-world data suggest that the incidence of esaxerenone-induced hyperkalemia may range from 3% to 12%, varying with underlying comorbidities and concomitant medications, underscoring the need for individualized risk assessment in clinical practice.

Pathophysiology

Esaxerenone, by antagonizing the mineralocorticoid receptor, inhibits aldosterone-mediated sodium reabsorption and potassium excretion in the distal nephron. While this mechanism underlies its antihypertensive and renoprotective effects, it simultaneously predisposes patients to hyperkalemia. The non-steroidal structure of esaxerenone confers higher receptor selectivity, potentially reducing off-target effects observed with older MRAs, but does not eliminate the fundamental risk of potassium retention. Factors such as impaired renal excretion, increased potassium intake, and drug-drug interactions further exacerbate hyperkalemia risk in susceptible individuals.

Risk Factors

Several patient-specific and iatrogenic risk factors potentiate the development of hyperkalemia during esaxerenone therapy. Advanced age, reduced glomerular filtration rate (GFR), diabetes mellitus, and concomitant use of RAAS inhibitors or potassium-sparing diuretics significantly increase susceptibility. Clinical trials and pharmacovigilance studies consistently identify CKD stage 3 or higher as a major risk factor, with hyperkalemia rates peaking in patients with eGFR <45 mL/min/1.73 m2. Additionally, baseline hyperkalemia, dietary potassium load, and genetic polymorphisms affecting renal handling of potassium contribute to risk stratification.

Clinical Features

Hyperkalemia associated with esaxerenone is often asymptomatic, especially in early or mild cases, highlighting the importance of routine laboratory monitoring. When symptomatic, patients may present with muscle weakness, paresthesia, or cardiac arrhythmias, including potentially fatal ventricular fibrillation. Electrocardiographic changes, such as peaked T waves, widened QRS complexes, and sine-wave patterns, are hallmarks of severe hyperkalemia. Prompt recognition of these clinical and electrocardiographic features is critical to prevent adverse outcomes, particularly in high-risk populations.

Diagnosis

Diagnosis of esaxerenone-induced hyperkalemia relies on serial serum potassium measurements, ideally within the first week of therapy initiation and after subsequent dose adjustments. Clinical guidelines recommend close monitoring, especially in patients with CKD, diabetes, or those taking interacting medications. Additional laboratory assessments, including renal function tests and acid-base status, aid in distinguishing hyperkalemia due to impaired excretion from pseudohyperkalemia or laboratory artifact. Electrocardiography is warranted in moderate to severe cases or when symptoms suggest cardiac involvement.

Treatment & Management

Management of hyperkalemia during esaxerenone therapy encompasses both preventive and therapeutic strategies. Dose titration and individualized patient selection are foundational, with initiation at lower doses in high-risk populations. Temporary or permanent discontinuation may be necessary in cases of persistent or severe hyperkalemia. Non-pharmacological interventions include dietary potassium restriction and avoidance of over-the-counter potassium supplements. Pharmacological management may involve potassium binders, loop diuretics, or adjustments in concomitant RAAS inhibitors. Patient education and shared decision-making are essential to optimize adherence and minimize adverse events.

Recent Advances / Emerging Therapies

Recent advances in the management of hyperkalemia include the development of novel potassium binders, such as patiromer and sodium zirconium cyclosilicate, which enable continued use of MRAs by mitigating hyperkalemia risk. Real-world studies and post-marketing surveillance of esaxerenone have further refined risk stratification tools and monitoring protocols, facilitating safer implementation in diverse clinical settings. Ongoing research is evaluating the long-term safety and efficacy of esaxerenone in broader populations, including those with heart failure and advanced CKD.

Guideline Recommendations

Current guidelines from the Japanese Society of Hypertension and the Kidney Disease: Improving Global Outcomes (KDIGO) initiative endorse the cautious use of esaxerenone, emphasizing patient selection, dose titration, and regular laboratory monitoring. In patients with moderate to severe CKD or those on polypharmacy, guidelines recommend more frequent potassium assessments and consideration of newer potassium-lowering agents. Shared decision-making, patient education, and interdisciplinary collaboration are highlighted to maximize therapeutic benefit while minimizing risk.

Conclusion

Esaxerenone represents a valuable addition to the armamentarium for hypertension and CKD with proteinuria, offering clinically meaningful benefits while presenting manageable risks when used judiciously. Hyperkalemia remains the principal safety concern, particularly in real-world practice where patient variability is high. Through careful patient selection, rigorous monitoring, and the judicious use of adjunct therapies, the risk of hyperkalemia can be mitigated. Continued research and real-world evidence are essential to further refine the safety profile of esaxerenone and ensure optimal outcomes for patients with complex comorbidities.